Cyproheptadine Dosing for Appetite Stimulation
For appetite stimulation, cyproheptadine should be dosed at 4 mg three times daily (12 mg/day total) in adults, with pediatric dosing of 2 mg (0.5 tablet) two to three times daily for ages 2-6 years and 4 mg two to three times daily for ages 7-14 years, based on FDA-approved labeling. 1
Adult Dosing
The FDA-approved dosing for adults specifies:
- Initial dose: 4 mg three times daily (12 mg/day)
- Therapeutic range: 4-20 mg/day
- Most patients require 12-16 mg/day
- Maximum dose: 32 mg/day (0.5 mg/kg/day should not be exceeded)
- Adjust according to patient size and response 1
This dosing is supported by clinical trial evidence showing efficacy at 4 mg three times daily (12 mg/day total) for 8-12 weeks, which demonstrated significant appetite improvement and weight gain in adults with poor appetite 2, 3.
Pediatric Dosing
Ages 2-6 years:
- Usual dose: 2 mg (½ tablet) two to three times daily
- Can calculate based on 0.25 mg/kg/day or 8 mg/m² body surface area
- Maximum: 12 mg/day 1
Ages 7-14 years:
- Usual dose: 4 mg (1 tablet) two to three times daily
- Maximum: 16 mg/day 1
Recent pediatric evidence supports 0.15 mg/kg twice daily in young children (ages 1-3 years) with failure to thrive, showing significant improvements in weight-based anthropometric indices after 12 weeks 4. For cystic fibrosis patients ages 5-18 years, 4 mg three times daily for 12 weeks produced significant weight gain and BMI improvements 5.
Duration of Treatment
Most clinical trials demonstrating efficacy used 8-12 week treatment courses 4, 2, 5. The medication appears most effective for short-term nutritional support rather than chronic progressive disease states.
Important Clinical Considerations
Efficacy varies by underlying condition:
- Strong evidence for weight gain in healthy individuals with poor appetite, children with failure to thrive, cystic fibrosis, and stimulant-induced weight loss 4, 2, 5, 6
- Minimal to no benefit in malignant/progressive disease states (HIV, cancer) - oncology guidelines rate cyproheptadine as having weak evidence (Level C) with reported adverse effects 7, 8
Common adverse effects:
- Somnolence/drowsiness is the most frequent side effect 2, 6, 3
- This sedation may actually benefit patients with stimulant-induced insomnia 6
- Generally well-tolerated with mild to moderate transient sedation 8
Guideline Context
The 2003 oncology guidelines for appetite stimulants recommend against routine use of cyproheptadine in cancer patients, noting it "may be an appetite stimulant, but adverse effects have been reported" with Level C evidence, suggesting it should only be used in clinical trial settings for this population 7. In contrast, the medication has FDA approval and strong evidence for non-malignant causes of poor appetite.
The medication works through antihistaminic and antiserotonergic mechanisms, likely disrupting serotonergic feeding pathways to enhance appetite and caloric intake 3, 8.